タキザワ　マキコ   TAKIZAWA Makiko   滝沢　牧子    所属   埼玉医科大学  医学部 総合医療センター　医療安全管理学    職種   教授
論文種別	学術雑誌(原著)
言語種別	中国語
査読の有無	査読なし
表題	Entecavirとdasatinibを併用し, 安全に治療継続し得たHBVキャリアの新規発症慢性骨髄性白血病慢性期
掲載誌名	正式名：北関東医学 ISSNコード：1343-2826
出版社	Kitakanto Medical Society
巻・号・頁	64(1),51-55頁
著者・共著者	武井 寿史,三井 健揮,佐藤 成,斉藤 明生,星野 匠臣,小磯 博美,滝沢 牧子,横濱 章彦,斉藤 貴之,塚本 憲史,村上 博和,半田 寛,野島 美久
発行年月	2014
概要	Oral administration of multikinase inhibitor dasatinib showed significantly higher and faster rates of CCyR and MMR than imatinib in patients with newly diagnosed chronic myeloid leukemina (CML) -chronic phase (CP). The reactivation of hepatitis B virus (HBV) is a well-known complication for HBV carrier treated with cytotoxic or immunosuppressive agent. Although dasatinib may act as an immunosuppressive agent, it is unclear whether dasatinib induces the reactivation of HBV. Here, we report the combination therapy with dasatinib and entecavir in newly diagnosed CML-CP patient with HBV carrier. A 63-year-old man with HBV carrier newly diagnosed as CML-CP. HBV DNA levels in serum showed 2.4 log copies/ml. Before administration of dasatinib, the patient received 0.5mg of entecavir daily. Six days later, HBV DNA levels decreased less than 2.1 log copies/ml. Then, lOOmg of dasatinib was administrated in combination with entecavir daily. Partial cytogenic response was achieved at day 90. At one year, major molecular response was achieved. Neither adversed events (AEs) of liver function nor evidence of reactivation of HBV was observed. Combination with entecavir and dasatinib is safe and effective therapy for newly diagnosed CML-CP with HBV carrier. Accumulation of such cases is necessary to optimize the treatment approach.
DOI	10.2974/kmj.64.51